Brookline Capital Markets Initiates a Buy Rating on Kura Oncology (KURA)
Brookline Capital Markets analyst Leah R. Cann initiated coverage with a Buy rating on Kura Oncology (KURA – Research Report) on February 24 and set a price target of $40.00. The company’s More »
Analysts Are Bullish on These Healthcare Stocks: Karuna Therapeutics (KRTX), Sensus Healthcare (SRTS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karuna Therapeutics (KRTX – Research Report) and Sensus Healthcare (SRTS – Research Report) with More »
